Marcus Guardian

EUnetHTA Chief Operating Officer (C.O.O.)

[EUnetHTA @EUnetHTA]

PTJA10 'crizanlizumab indicated for the prevention of recurrent vaso-occlusive crises in sickle cell disease patients aged 16 years and over' – project plan is now available.

The final assessment report will be published on 21 October, 2020.

https://t.co/ME7TXmIUmp

#eunethta

[EUnetHTA @EUnetHTA]

EUnetHTA has published of the first pharmaceutical Plain Language Summary. This summary addresses PTJA04 on sotagliflozin for adult patients with type 1 diabetes with a high BMI. For any questions, please reach out to [email protected].

https://t.co/RBZE80mhWA

#hta

[EUnetHTA @EUnetHTA]

The 19th @EMA_News/@EUnetHTA bilateral meeting is taking place today. Among the topics on the agenda: revised framework for discussions on product developments and practical application of extrapolation of evidence for regulators & HTA bodies.

#EMA #eunthta #hta

[EUnetHTA @EUnetHTA]

EUnetHTA Early Dialogues – Status during EUnetHTA prolongation period

Please follow the link for an update on EDs through end of May, 2021.

https://t.co/humks2kckj

#eunethta #hta

[EUnetHTA @EUnetHTA]

EUnetHTA is pleased to announce that the "Rapid Collaborative Review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic" is now available. 

Access here:

https://t.co/DqZT82hCXJ

#COVIDー19 #hta #eunethta

[EUnetHTA @EUnetHTA]

EUnetHTA Response to COVID-19

Please follow the link to read more:

https://t.co/Vwr2ShBXnR

#COVIDー19 #eunethta #COVID19

[EUnetHTA @EUnetHTA]

EUnetHTA Response to COVID-19

Please follow the link to read more:

https://t.co/Vwr2ShBXnR

#COVIDー19 #eunethta #COVID19

[EUnetHTA @EUnetHTA]

Statement from the EUnetHTA Secretariat on COVID-19.

Please follow the link for more information:

https://t.co/1YfO1JBbA2

#eunethta #COVIDー19

[EUnetHTA @EUnetHTA]

PTJA07 Final Assessment Report is now available

This is the 7th EUnetHTA Pharmaceutical Joint Assessment.

Follow this link for details and access:

https://t.co/ydh4Sgp3cy

#eunethta #hta #jointassessment

[EUnetHTA @EUnetHTA]

EUnetHTA Magazine - Autumn 2019 - Now Available

Follow the link for your update on HTA:

https://t.co/H3izGyAFGR

#eunethta #hta

[EUnetHTA @EUnetHTA]

Open Call for Patient Input for a new Joint Assessment on a medicinal product for de novo or secondary acute myeloid leukaemia.

Input submissions will be received through 28th November, 16:00 CEST.

Follow this link:

https://t.co/D4K7xPojkM

#hta #eunethta #opencall

[EUnetHTA @EUnetHTA]

Open Call for Patient Input - Joint Assessment on a medicinal product for the prevention of vaso-occlusive crises in sickle cell disease (SCD) patients aged 16 years and over.

For more info on participation, follow the link:

https://t.co/quod230KVS

#hta #eunethta #sicklecell

[Marcus Guardian @GuardianCMarcus]

@GretaThunberg Please know that your supporters are outnumbering those burdening you with their negativity and lies! Your actions are warning and inspiration to all generations!

[EU Medicines Agency @EMA_News]

First ‘histology-independent’ treatment for solid tumours with a specific gene mutation recommended for approval https://t.co/HUM1mYgzkM #CHMP

[EUnetHTA @EUnetHTA]

An Understanding of EUnetHTA HTA

The EUnetHTA Executive Board recently adopted an Understanding of EUnetHTA HTA. This text is the result of several months of consultation with the project’s board.

#eunethta #hta

To see more, follow the link:

https://t.co/NQraJ8XW0t

[EUnetHTA @EUnetHTA]

OTJA10 'Stool DNA testing for early detection of colorectal cancer' final assessment report, with comments from manufacturers and external experts, are now available for access.

#eunethta #medicaldevices #medtech #hta

Please follow this link:

https://t.co/dqfXVf5RUt

[EUnetHTA @EUnetHTA]

EUnetHTA Prioritisation List (EPL) 2.0 is now available.

The EPL provides a topic listing that helps both national bodies and companies foster collaboration on specific areas of significant interest.

#eunethta

Follow the link to access the EPL 2.0:

https://t.co/zaR0gO7Tow

[Michelle Mujoomdar @M_Mujoomdar]

So pleased that our paper has been published in PharmacoEconomics Open! @JacolineBouvy and I are delighted by the support we received from the #HEOR #HTA community. Thank you @ApplHealthEcon for your support and thank you @nancydevlin1 for you thoughtful and considered response.

[EUnetHTA @EUnetHTA]

Reminder: Open Call for Patient Input – Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD).

To participate before 15th July closing, follow this link:

https://t.co/PmnysDXIiy

[EUnetHTA @EUnetHTA]

We are pleased to announce that the final assessment for OTCA15 “Irreversible electroporation in liver and pancreatic cancer", together with the input from external experts and manufacturers, are now available for access at this link:

https://t.co/2YMEOkcYtu